Goldman Sachs Maintains Buy on Versigent, Lowers Price Target to $58
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.
Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.